

Basel, 8 May 2018

## **Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting**

- **New and updated pivotal combination data from the Tecentriq lung programme, including overall survival (OS) results from IMpower150 and progression free survival (PFS) results from IMpower131**
- **New, longer follow-up data from the Phase III ALEX study of Alecensa in ALK-positive lung cancer**
- **Pivotal data from the haematology clinical development programme, including new data for Venclexta and polatuzumab vedotin**

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its early and late-stage clinical studies, on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States. More than 180 abstracts have been accepted across 13 cancer types, including two “late breakers” and 15 oral presentations.

“New data to be presented from our industry-leading oncology portfolio, including our lung and haematology programmes, will demonstrate how our science-driven approach aims to improve outcomes for people living with cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “At ASCO, we look forward to sharing our progress and commitment to build the future of personalised healthcare in oncology.”

An analyst briefing to discuss key data presented on the Roche Group's oncology products and pipeline at ASCO 2018 will take place on Monday 4 June from 5:30 -7:00 pm CDT at the Marriott Downtown Chicago

**F. Hoffmann-La Roche Ltd**

4070 Basel  
Switzerland

Investor Relations  
email:  
investor.relations@roche.com

Tel. +41 61 68-88880  
Fax +41 61 69-10014  
www.roche.com

Magnificent Mile. This event, independently organized by Roche, is open to analysts and investors who have registered for the event. **To register for the event**, please follow the [link](#) (Password: Analyst2018).

Follow Roche on Twitter via @Roche and keep up to date with ASCO 2018 congress news and updates by using the hashtag #ASCO18.

### **Key presentations in lung cancer**

Key data to be presented at ASCO cover advances from Roche's lung cancer programme, including a combination approach using the cancer immunotherapy, Tecentriq® (atezolizumab) with targeted therapies and a range of different chemotherapies.

Updated OS data and new patient reported outcomes (PROs) data from the Phase III IMpower150 study of Tecentriq plus Avastin® (bevacizumab) and chemotherapy (carboplatin and paclitaxel), in people with previously-untreated, advanced non-squamous non-small cell lung cancer (NSCLC), will be presented. The US Food and Drug Administration (FDA) recently granted Priority Review for this combination in the same patient population.

New PFS results from the Phase III IMpower131 study of Tecentriq plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; *nab*-paclitaxel]) as an initial (first-line) treatment for people with advanced squamous NSCLC will also be shared and feature as part of ASCO's official press programme on Saturday, 2 June.

Additional results in lung cancer include longer follow-up results from the Phase III ALEX study of Alecensa® (alectinib) versus crizotinib in people with previously untreated anaplastic lymphoma kinase (ALK)-positive NSCLC. These data build on the primary results from the ALEX study, first presented at ASCO 2017, which demonstrated a significant reduction in the risk of disease progression or death versus crizotinib. New data that utilise the application of a real world endpoint to identify and characterise genetic profiles of people with a poor prognosis in advanced NSCLC will also be presented at the congress.

### **Additional presentations with cancer immunotherapy**

Additional cancer immunotherapy data presentations of note include new Tecentriq plus Avastin PROs from the Phase III IMmotion151 study in advanced renal cell carcinoma (RCC), and Phase Ib data for the combination of Tecentriq plus Avastin in first-line hepatocellular carcinoma (HCC). These studies add to the growing body of evidence that support the use of Tecentriq plus Avastin across multiple tumour types. New tumour mutational burden (TMB) data from two studies of Tecentriq will also be presented, including blood-based TMB data from the Phase II B-FIRST study in advanced NSCLC, and tissue-based TMB data across multiple tumour types including NSCLC, metastatic urothelial carcinoma and melanoma.

### **Key presentations in blood cancers**

Data from pivotal studies in haematology will also be presented at ASCO. Additional analyses on minimal residual disease (MRD) rates will be shared from the Phase III MURANO study evaluating Venclexta®/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab), compared to bendamustine plus MabThera/Rituxan, in people with relapsed or refractory chronic lymphocytic leukaemia (CLL). A supplemental new drug application (sNDA) based on the MURANO data was granted Priority Review by the FDA, with an action date of 28 June 2018.

Additional data will also be presented from the Phase Ib M14-358 study of Venclexta/Venclyxto plus azacitidine or decitabine in people with previously untreated acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. Venclexta/Venclyxto is being developed by AbbVie and Roche.

Data from the randomised Phase II study evaluating polatuzumab vedotin in combination with bendamustine chemotherapy and MabThera/Rituxan in people with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) will also be presented at the meeting.

### **Key presentations in breast cancer**

Updates from two investigational medicines in breast cancer will be presented at ASCO. Data includes results from the Phase III SANDPIPER study of taselisib (GDC-0332) and fulvestrant, compared to fulvestrant alone, in estrogen receptor (ER)-positive, PIK3CA-mutant, locally advanced or metastatic breast cancer, and

updated OS data from the LOTUS trial of ipatasertib (GDC-0068, RG7440) and paclitaxel for previously untreated, locally advanced or metastatic, triple-negative breast cancer. The SANDPIPER data will be featured as part of ASCO's official press programme on Saturday, 2 June.

### Overview of key presentations featuring Roche medicines at ASCO 2018

Medicine	Abstract title	Abstract number
Tecentriq (atezolizumab) <i>(investigational use)</i> Avastin (bevacizumab) <i>(investigational use)</i>	Overall survival (OS) analysis of IMpower150, a randomised Phase 3 study of Atezolizumab plus chemotherapy plus bevacizumab vs chemotherapy plus bevacizumab in 1L non-squamous NSCLC	Abstract 9002 (oral) Monday 04 June 15:45 – 15:57 CDT
Tecentriq (atezolizumab) <i>(investigational use)</i>	IMpower131: Primary PFS and safety analysis of a randomised phase III study of atezolizumab + carboplatin and paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC.	Abstract LBA9000 (oral) Monday 04 June 15:00 – 15:12 CDT
Alecensa (alectinib)	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC	Abstract 9043 (poster #366) Sunday 03 June 08:00 – 11:30 CDT
Tecentriq (atezolizumab) <i>(investigational use)</i> Avastin (bevacizumab) <i>(investigational use)</i>	Patient-reported outcomes (PROs) in the randomised, phase III IMpower150 study of Atezolizumab plus chemotherapy plus bevacizumab vs chemotherapy plus bevacizumab in 1L non-squamous metastatic NSCLC	Abstract 9047 (poster #370) Sunday 03 June 08:00 – 11:30 CDT
Tecentriq (atezolizumab) <i>(investigational use)</i>	Prospective clinical evaluation of blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab in 1L non-small cell lung cancer (NSCLC): Interim B-FIRST results.	Abstract 12001 (oral) Tuesday 05 June 08:12 – 08:24 CDT
Tecentriq (atezolizumab) <i>(investigational use)</i>	Association of high tissue TMB and atezolizumab efficacy across multiple tumour types.	Abstract 12000 (oral) Tuesday 05 June 08:00 – 08:12 CDT

Tecentriq (atezolizumab) <i>(investigational use)</i>  Avastin (bevacizumab) <i>(investigational use)</i>	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab plus bevacizumab vs sunitinib in treatment naive metastatic renal cell carcinoma (mRCC).	Abstract 4511 (oral) Sunday 03 June 08:24 – 08:36 CDT
Tecentriq (atezolizumab) <i>(investigational use)</i>  Avastin (bevacizumab) <i>(investigational use)</i>	Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).	Abstract 4074 (poster #263) Sunday 03 June 08:00 – 11:30 CDT
Tecentriq (atezolizumab)	Atezolizumab in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase II study IMvigor210.	Abstract 4523 (poster #349) Saturday 02 June 08:00 – 11:30 CDT
Tecentriq (atezolizumab)  <i>(investigator study)</i>	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).	Abstract 4506 (oral) Sunday 03 June 10:00 – 10:12 CDT
Tecentriq (atezolizumab) <i>(investigational use)</i>  Alecensa (alectinib) <i>(investigational use)</i>	Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in <i>ALK</i> + advanced NSCLC (aNSCLC).	Abstract 9009 (oral) Friday 01 June 16:42 – 16:54 CDT
Polatuzumab <i>(investigational use)</i>	Randomised phase II trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.	Abstract 7507 (oral) Sunday 03 June 11:45 – 11:57 CDT
Venclexta/Venclyxto <i>(investigational use)</i>	Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).	Abstract 7010 (oral) Monday 04 June 17:06 – 17:24 CDT
Venclexta/Venclyxto <i>(investigational use)</i>	High, durable minimal residual disease negativity (MRD-) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.	Abstract 7508 (oral) Sunday 03 June 11:57 – 12:09 CDT

Venclexta/Venclyxto ( <i>investigational use</i> )	Phase II study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.	Abstract 8004 (oral) Friday 01 June 15:57 – 16:09 CDT
Taselisib ( <i>investigational use</i> )	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.	Abstract LBA1006 (oral) Sunday 03 June 10:00 – 10:12 CDT
Ipatasertib ( <i>investigational use</i> )	Overall survival (OS) update of the double-blind placebo controlled randomized phase II LOTUS trial of first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-negative breast cancer (mTNBC).	Abstract 1008 (oral) Sunday 03 June 10:24 – 10:36 CDT
Entrectinib ( <i>investigational use</i> )	Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumours.	Abstract 10536 (poster #209) Saturday 02 June 08:00 – 11:30 CDT
Real World Data	Application of a real world endpoint to identify and characterise genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC).	Abstract 12006 (oral) Tuesday 05 June 10:00 – 10:12 CDT

### About Roche in Oncology

Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche's commitment to developing innovative medicines and diagnostics for cancers remains steadfast.

The Roche Group's portfolio of innovative cancer medicines includes: Alecensa® (alectinib); Avastin® (bevacizumab); Cotellic® (cobimetinib); Erivedge® (vismodegib); Gazyva®/Gazyvaro® (obinutuzumab); Herceptin® (trastuzumab); Kadcyla® (trastuzumab emtansine); MabThera®/Rituxan® (rituximab); Perjeta® (pertuzumab); Tarceva® (erlotinib); Tecentriq® (atezolizumab); Venclexta®/Venclyxto™ (venetoclax); Xeloda® (capecitabine); Zelboraf® (vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies.

For more information on Roche's approach to cancer, visit [Roche.com](http://Roche.com).

### **About Roche**

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com).

All trademarks used or mentioned in this release are protected by law.

Abraxane is a registered trademark of Abraxis Bioscience, LLC, a wholly owned subsidiary of Celgene Corporation.

### **Roche Investor Relations**

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: [karl.mahler@roche.com](mailto:karl.mahler@roche.com)

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: [sabine.borngraeber@roche.com](mailto:sabine.borngraeber@roche.com)

Dr. Bruno Eschli  
Phone: +41 61 68-75284  
e-mail: [bruno.eschli@roche.com](mailto:bruno.eschli@roche.com)

Dr. Susann Manchado  
Phone: +41 61-68-75619  
e-mail: [susann.manchado@roche.com](mailto:susann.manchado@roche.com)

Dr. Birgit Masjost  
Phone: +41 61 68-84814  
e-mail: [birgit.masjost@roche.com](mailto:birgit.masjost@roche.com)

**Investor Relations North America**

Loren Kalm  
Phone: +1 650 225 3217  
e-mail: [kalm.loren@gene.com](mailto:kalm.loren@gene.com)